NRIX · Nurix Therapeutics, Inc.
$27.05
-0.74 (-2.66%)
At close · Aug 20
Market Cap
$2.88B
Shares
103.78M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$27.05
Open$27.33
Day$26.68–27.57
52W close$8.24–27.79
Avg vol 30d1.1M
Short int18.4M · 17.7% float · 18.0d
Short vol65%
Last earningsJul 9, 2026
DataJul 2020–Aug 2026
Filing10-Q · Jul 9
Up next
Next earnings call
Jul 12, 2027
Est · unconfirmed
· in 46 wks
FQ3-26 quarter ends
~Aug 30, 2026
Est
filed Jul 9, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+49%
above
Price vs 50-day avg
+17%
above
RSI (14)
67
neutral
MACD trend
Positive
52-week position
96%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+14%
trailing
6-month return
+69%
trailing
YTD return
+43%
this year
Relative strength
+58%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $23 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +47 funds added
Insider flow
Distributing
Net -$246.4K over 90 days · 100% sells
Short interest
Rising
17.68% of float · ▲ +2.1% MoM · 18.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
212 holders — near 3-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
+99%
Y/Y
EPS growth
−6%
Y/Y
Free cash flow
$-263.5M
Balance sheet
$247.0M
net cash
Quant / Vol
risk profile
Volatility
61%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
3.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+49%
Bullish
Price vs 50-day avg
+17%
Bullish
RSI (14)
67
Neutral
MACD trend
Positive
Bullish
52-week position
96%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $23 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +47 funds added
Insider flow
Distributing
Net -$246.4K over 90 days · 100% sells
Short interest
Rising
17.68% of float · ▲ +2.1% MoM · 18.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
212 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $8
Now $27 · 96%
Range high $28
vs 200-day avg +49%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NRIX
this stock
Nurix Therapeutics, Inc.
|
$2.88B | +42.6% | +99.3% | — | 17.7% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NRIX | -0.5% | +13.9% | +69.4% | +16.5% | +42.6% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +1.5% | +10.6% | +58.2% | +14.5% | +30.8% |
Key facts
CIK
1549595
CUSIP
67080M103
13F (30d)
208 filings
201 filers
Visit website
Investor relations